• In March 2026, Arrowhead Pharmaceuticals reported two-year open-label extension data showing durable triglyceride reductions and consistent safety for investigational plozasiran in patients with severe and mixed hypertriglyceridemia, building on earlier Phase 2b results and supporting ongoing global Phase 3 programs and regulatory plans.
• The data underscored plozasiran’s potential to address a lack of long-term treatment options in severe lipid disorders, including rare Familial Chylomicronemia Syndrome, by targeting apoC-III via RNA interference to sustain clinically meaningful triglyceride lowering.
• We’ll now examine how this long-term plozasiran efficacy and safety profile may reshape Arrowhead’s investment narrative and future risk‑reward balance.

We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Arrowhead Pharmaceuticals Investment Narrative Recap

To own Arrowhead, you need to believe its RNAi platform can sustain a multi-drug cardiometabolic franchise while it manages high R&D spend and dependence on partnerships. The new two-year plozasiran data directly supports the key near term catalyst of Phase 3 SHASTA and MUIR readouts and planned 2026 filings, while the biggest current risk remains potential regulatory or late-stage clinical setbacks across this concentrated pipeline.

Among recent announcements, the approval of REDEMPLO (plozasiran) in the U.S., Canada, and China for FCS is most relevant here, because it anchors plozasiran as a commercial product while the new HTG data builds the case for broader indications. Together, these events frame the upcoming Phase 3 results and planned sNDA as central value drivers, but they also heighten the impact if timelines slip or regulators view the data differently than investors expect.

Yet against this encouraging data, investors still need to think carefully about how concentrated late stage RNAi risk could affect Arrowhead’s...

Arrowhead Pharmaceuticals’ narrative projects $398.8 million revenue and $64.0 million earnings by 2028.

Uncover how Arrowhead Pharmaceuticals' forecasts yield a $64.08 fair value, a 5% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts already expected revenues near US$840,000,000 by 2029, so this new plozasiran data could either reinforce or challenge that outlook depending on how you weigh the risk that heavy RNAi concentration and funding needs might still limit how much of that upside is realized.

Explore 2 other fair value estimates on Arrowhead Pharmaceuticals - why the stock might be worth just $64.08!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Arrowhead Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Arrowhead Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arrowhead Pharmaceuticals' overall financial health at a glance.

Looking For Alternative Opportunities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Find 58 companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with 33 elite penny stocks that balance risk and reward.
• This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.